St. Vincent Hospital, The Catholic University of Korea, Paldal-gu, Ji-dong 93-6, Suwon, Korea South.
Curr Eye Res. 2013 Jan;38(1):9-17. doi: 10.3109/02713683.2012.720340. Epub 2012 Aug 28.
To compare the effect of autologous serum eye drops with different diluents in patients with dry eyes and persistent epithelial defects.
Patients of Sjögren's syndrome (Group I), non-Sjögren's syndrome (group II) with dry eye, and persistent epithelial defects (Group III) were included. The eyes of each group were randomly treated with one of the following autologous serum eye drops: 100% serum (AS(100)), 50% serum with normal saline (AS(50NS)); 50% serum with sodium hyaluronate (AS(50HA)); or 50% serum with ceftazidime (AS(50CEF)). The differences in dry eye symptoms, Schirmer test I, tear break-up time (TBUT), corneal staining, and speed in epithelial healing were studied.
In Group I, AS(100) showed fewer symptoms than AS(50NS), AS(50HA) and AS(50CEF) (all p < 0.01). AS(100) showed significantly better effect than AS(50NS), AS(50HA) and AS(50CEF) in decreasing corneal staining at the time point of 12-week post-treatment (p = 0.041, p < 0.001 and p < 0.001, respectively). In Group II, AS(100) was more effective than AS(50CEF) in decreasing symptoms and decreasing corneal staining (all p < 0.05). There was no significant difference in symptom and corneal staining between AS(100) and AS(50NS). In Group III, AS(100) was the most effective in achieving quick epithelial closure.
In the eyes with Sjögren syndrome and persistent epithelial defects, AS(100) was the most effective in decreasing symptoms, corneal epitheliopathy and promoting fast closure of wound. In the eyes with non-Sjögren syndrome, AS(100) and AS(50NS) have similar effects in decreasing symptoms and corneal epitheliopathy.
比较不同稀释剂的自体血清滴眼液对干眼症和持续性上皮缺损患者的疗效。
纳入干燥综合征患者(I 组)、非干燥综合征干眼症患者(II 组)和持续性上皮缺损患者(III 组)。每组患者的眼睛随机接受以下一种自体血清滴眼液治疗:100%血清(AS(100))、50%血清加生理盐水(AS(50NS))、50%血清加透明质酸钠(AS(50HA))或 50%血清加头孢他啶(AS(50CEF))。研究干眼症症状、Schirmer 试验 I、泪膜破裂时间(TBUT)、角膜染色和上皮愈合速度的差异。
在 I 组中,AS(100)在缓解症状方面优于 AS(50NS)、AS(50HA)和 AS(50CEF)(均 p<0.01)。在治疗后 12 周时,AS(100)在减少角膜染色方面的效果明显优于 AS(50NS)、AS(50HA)和 AS(50CEF)(p=0.041、p<0.001 和 p<0.001)。在 II 组中,AS(100)在缓解症状和减少角膜染色方面的效果优于 AS(50CEF)(均 p<0.05)。AS(100)与 AS(50NS)在症状和角膜染色方面无显著差异。在 III 组中,AS(100)在促进上皮快速愈合方面最有效。
在干燥综合征伴持续性上皮缺损的眼中,AS(100)在缓解症状、角膜上皮病变和促进伤口快速愈合方面最有效。在非干燥综合征的眼中,AS(100)和 AS(50NS)在缓解症状和角膜上皮病变方面效果相似。